Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

Production of biologic active ingredients at the site is scheduled to start in 2026. Part of the Limerick site's production capacity has been earmarked for donanemab, which was approved by the US ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.

That includes Lilly's Alzheimer's candidates, currently headed by amyloid-targeting drug donanemab which was ... facility for active pharmaceutical ingredients (APIs) in Dublin, creating 100 ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly ...